Immunotherapy has revolutionized clinical outcomes in both early-stage and advanced-stage malignancies. Immunotherapy has improved patient survival in both solid and hematologic disorders with the potential added benefit of less toxicity compared to conventional cytotoxic chemotherapy. Imaging plays a fundamental role in monitoring treatment response and assessment of immune-related adverse events, e.g. pneumonitis, colitis, etc. Familiarity with the current strategies of immune-related response evaluation and their limitations is essential for radiologists to guide clinicians with their treatment decisions. Radiologists should be aware of the wide spectrum of immune-related adverse events and their various radiological features as well as the patterns of treatment response associated with immunotherapies.
Keywords: Imaging; Immune Response Evaluation Criteria in Solid Tumors (iRECIST); Immune-related Response Evaluation Criteria in Solid Tumors (irRECIST); Immune-related response criteria (irRC); Immunotherapy; Response Evaluation Criteria in Solid Tumors.
Copyright © 2021 Elsevier B.V. All rights reserved.